Activity and research directory

This project involves using whole genome sequencing of E. coli and other microbes frequently found in pigs. This will help track the spread of antimicrobial resistance (AMR) genes.

This project uses whole genome sequencing of avian pathogenic E. coli (APEC) to demonstrate that Australian APEC carry few antimicrobial resistance (AMR) genes in comparison with overseas APEC.

The Australian Centre for Genomic Epidemiological Microbiology (AusGEM) is using genomic sequencing to characterise Escherichia coli that cause urinary tract infections and sepsis in Australian hospitals.

Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health and Aged Care. It disseminates information on the epidemiology, surveillance, prevention and control of communicable diseases relevant to Australia.

This project involves developing a One Health surveillance system for Fiji to identify antimicrobial resistance (AMR) hot spots and improve AMR management.

This project involves using artificial intelligence to track, trace and tackle antimicrobial resistance (AMR).

This project aims to improve the usability of the Electronic Therapeutic Guidelines including developing a smartphone app.

Develop and pilot an antimicrobial stewardship program appropriate for use in companion animal veterinary practices.

CO-ADD screens compounds being used for academic research for antimicrobial activity. This is done for free.

SEQUAL aims to help residential aged care facilities implement a program of antimicrobial stewardship.

The National Antimicrobial Prescribing Survey (NAPS) is a standardised auditing tool designed to help health care facilities assess the quantity and quality of local antimicrobial prescribing.

The National Centre for Antimicrobial Stewardship (NCAS) is a health services research program that promotes the rational use of antimicrobial drugs throughout Australia.

The Guidance Group helps hospitals and other clinical facilities to improve their prescribing.

The Wollongong Antimicrobial Resistance Research Alliance (WARRA) is an initiative of the University of Wollongong, NSW. It aims to generate evidence on antibiotic use and drivers of antimicrobial resistance, to inform future interventions targeting the Illawarra Shoalhaven region.

The Wollongong Antimicrobial Resistance Research Alliance (WARRA) are conducting a longitudinal study across the Illawarra Shoalhaven region to look at the impact of antimicrobial resistance.

This Wollongong Antimicrobial Resistance Research Alliance (WARRA) project aims to examine the relationship between antimicrobial resistance and patient health care service utilisation rates and clinical outcomes across the Illawarra Shoalhaven region.

The Wollongong Antimicrobial Resistance Research Alliance (WARRA) aim to identify trends in antimicrobial resistance across the Illawarra Shoalhaven region.

This Wollongong Antimicrobial Resistance Research Alliance (WARRA) project is looking at predicting the use and misuse of antibiotics by developing a questionnaire.

The Wollongong Antimicrobial Resistance Research Alliance (WARRA) have developed a series of workshops to help tackle antimicrobial resistance.

This PhD research project is aimed at investigating alternative regulatory and funding models for antimicrobial drugs.

Antimicrobial Resistance: Science, Communication and Public Engagements (AMR-scapes) is an Australian research project examining how the public engages with advice about the rational and reduced use of antibiotics.

This collaborative research project is analysing the increase in antimicrobial resistance (AMR) in hospitals in Wenzhou, China.

This collaborative research project is isolating clinically effective ‘cocktails’ of bacteriophages that kill bacteria resistant to antimicrobials.

This project is developing new drugs for bacteria resistant to antimicrobials. By augmenting the host’s immune response and removing bacterial evasion mechanisms, it is hoped to overcome bacterial infections.

This project is exploring the properties of new vancomycin derivatives that will address growing bacterial resistance to these compounds.